BioLife Solutions Stock Today

Stock Highlights

BioLife Solutions (BLFS) is listed on NASDAQ Exchange in USA. BioLife Solutions is categorized in the Health Care Equipment & Supplies sector. The company conducts business in the Health Care Equipment & Supplies sector. At roughly 951.51 M, BioLife Solutions belongs to the small-cap segment of health care equipment & supplies companies. Useful market capitalization details here include about 48.3 M shares outstanding, enterprise value near 880 M, and a workforce of about 155 people. The company has 3.1 M shares sold short (6.24 days to cover). A negative net margin of 4.78% indicates the company is not currently profitable on a net income basis. The elevated P/E of 173.59 combined with ROE of -3.37% may reflect growth expectations beyond current return levels. The company reported previous year's revenue of 96.21 M. Net Loss for the year was -4.59 M with profit before overhead, payroll, taxes, and interest of 62.12 M. BioLife Solutions financial stability analysis Ownership Allocation The majority of BioLife Solutions' outstanding shares are owned by institutional investors. High institutional ownership often reflects the stock's eligibility for passive index funds, which are required to hold positions proportional to index weights regardless of their own investment view. Active managers holding BioLife Solutions must also disclose positions above certain thresholds through SEC filings. Institutions collectively hold about 97% of BioLife Solutions' shares, insiders own approximately 3%, and the remaining 0% is in public hands. Check BioLife Ownership Details

BioLife Solutions Hype to Price Pattern

Open Interest Against 2026-04-17 BioLife Option Contracts

Current option-chain data for BioLife Solutions covers the April 17, 2026 expiration. The chain lists 18 contracts (9 calls, 9 puts). At a glance, metrics point to implied volatility near 1.74 and put/call open-interest ratio around 0.05. Strike-level open interest is available in the full chain. View more details.ESG Sustainability

Environmental

Governance

Social

Notable Updates

CEO and President and Director	Michael Rice
Chairman	Aby Mathew
Vice President of Marketing	Todd Berard
Vice President - Operations	Karen Foster
Business Concentration	Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Composite Total, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors)
Average Analyst Recommendation 9 Opinions
Financial Strength BioLife Solutions (BLFS) recorded a Gross Profit Margin of 42.0%, an Operating Margin of -0.3%, and a Return On Assets of -3.1%. BioLife Solutions combines operating scale with pressured financial positioning. The earnings picture reflects near-term margin compression relative to deployed assets. Current Value Last Year Change From Last Year  10 Year Trend Asset Turnover 0.23 0.237 Sufficiently Down Slightly volatile Gross Profit Margin 0.42 0.6456 Way Down Slightly volatile Total Current Liabilities 24.1 M 23 M Sufficiently Up Slightly volatile Non Current Liabilities Total 7.1 M 11 M Way Down Slightly volatile Total Assets 426.2 M 405.9 M Sufficiently Up Slightly volatile Total Current Assets 126.2 M 120.2 M Sufficiently Up Slightly volatile
Debt Levels BioLife Solutions (BLFS) recorded $1.70 in Net Debt To EBITDA, a Debt To Equity of 0.09x, and $7.8 million in Long Term Debt. Supporting metrics include a Long Term Debt To Capitalization of 2.7% and $2.3 million in Long Term Debt Total, which analysts use to evaluate BioLife Solutions's operational efficiency. Current Assets BioLife Solutions (BLFS) recorded $0.33 in Intangibles To Total Assets, $426.2 million in Total Assets, and a Return On Assets of -3.1%. Supporting metrics include a Return On Tangible Assets of -6.6%, which analysts use to evaluate BioLife Solutions's operational efficiency.

Earnings per Share Projection vs Actual

Top Institutional Holders

Institutional Holdings for BioLife Solutions represents the portion of its shares owned by pension funds and asset managers. Institutional holders can acquire large blocks of BioLife Solutions' shares and influence corporate governance.

BioLife Solutions Historical Income Statement

Based on recent performance metrics, Depreciation And Amortization is expected to increase noticeably. BioLife Solutions last posted Depreciation And Amortization of 9.96 Million. As of March 26, 2026, Research Development is estimated to increase to approximately 7.9 M, while EBIT is moving lower toward slightly above -6.7 M. View More Fundamentals

BioLife Solutions Against Markets